Vimarsana
Biggest News Aggregation in the World

Page 13 - Allogeneic News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Allogeneic. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Allogeneic Today - Breaking & Trending Today

Priothera - FDA and EMA Grant Orphan Drug Designation to mocravimod for the treatment of Acute Myeloid Leukemia (AML) in patients undergoing allogeneic hematopoietic stem cell transplantation (HSCT) - Vimarsana News

Priothera - FDA and EMA Grant Orphan Drug Designation to mocravimod for the treatment of Acute Myeloid Leukemia (AML) in patients undergoing allogeneic hematopoietic stem cell transplantation (HSCT)

- Mocravimod is being developed as a potential best-in-class adjunctive and maintenance therapy to enhance the curative potential of HSCT for AML patients - A global registration-enabling

Tessa Therapeutics Showcases Positive Clinical Data from - Vimarsana News

Tessa Therapeutics Showcases Positive Clinical Data from

Oral poster presentation highlights data from dose-escalation trial of allogeneic CD30.CAR EBVST cell therapy (TT11X) in patients with relapsed or...

Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(4) - Vimarsana News

Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(4)

SOUTH SAN FRANCISCO - Atara Biotherapeutics, Inc. , a leader in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with cancer... | December 6, 2021

EMA to review Atara's MAA submission for allogeneic T-cell therapy: 'A watershed moment for the field' - Vimarsana News

EMA to review Atara's MAA submission for allogeneic T-cell therapy: 'A watershed moment for the field'

The EMA has validated Atara Biotherapeutics' Marketing Authorization Application (MAA) for tabelecleucel (tab-cel), the first time an off-the-shelf allogeneic T-cell therapy will be evaluated by any regulatory agency in the world.

Celyad Oncology to Present Updates from Allogeneic and Autologous CAR T Programs at 63rd ASH Annual Meeting and Exposition - Vimarsana News

Celyad Oncology to Present Updates from Allogeneic and Autologous CAR T Programs at 63rd ASH Annual Meeting and Exposition

Two abstracts will be presented in a pre-recorded poster presentation and oral session Regulatory News: Celyad Oncology SA (Brussels:CYAD) (Paris:CYAD) (NASDAQ:CYAD) (Euronext Nasdaq: CYAD)